NCT05922878ClinicalTrials.gov
Study of ALTO-300 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
In breve
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Fase 2325 partecipanti ricercati75 centri1 paese
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT05922878Apri questa scheda su ClinicalTrials.govSincronizzato 3 settimane fa
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 325 participants (target), run at 75 sites.
How this score is built
- Enrolment24/40
321 participants (target)
- Site count19/25
45 sites
- Country count0/15
Single country
- Planned duration8/10
Planned over about 42 months
- Sponsor scale2/10
Alto Neuroscience has led 5 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Patologie
- Major Depressive Disorder
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – 70 Years |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Fase 2 |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | TREATMENT |
| Mascheramento | QUADRUPLE (4) |
| Arruolamento | 325 partecipanti ricercati |
Sponsor e collaboratori
- Alto Neuroscience Sponsor
Bracci e interventi
- ALTO-300EXPERIMENTAL
Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).
- PlaceboPLACEBO_COMPARATOR
Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.
Interventi
- Farmaco ALTO-300
ALTO-300 capsule QD
- Farmaco Placebo
Placebo capsule QD
Esiti misurati
Esito primario
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Orizzonte temporale Change over time for up to week 6
Esito secondario
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Orizzonte temporale Change over time for up to week 6
Esito secondario
To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
Orizzonte temporale Change over time for up to week 6
Esito secondario
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.
Incidence, severity, and relatedness of Adverse Events
Orizzonte temporale Assessed from Day 1 to Week 14
Esito secondario
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.
Assessment of Heart Rate
Orizzonte temporale Assessed from Day 1 to Week 14
Esito secondario
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.
Assessment of Weight Change
Orizzonte temporale Assessed from Day 1 to Week 14
Esito secondario
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.
Assessment of Blood Pressure
Orizzonte temporale Assessed from Day 1 to Week 14
Esito secondario
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).
The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.
Orizzonte temporale Assessed from Day 1 to Week 15
Date
| Data di inizio | 8 giugno 2023 (effettiva) |
|---|---|
| Conclusione primaria | 1 dicembre 2026 (stimata) |
| Conclusione | 1 dicembre 2026 (stimata) |
| Prima pubblicazione | 28 giugno 2023 (effettiva) |
| Ultimo aggiornamento | 26 ottobre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | ottobre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
30 centri stanno reclutando
United States
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Site 114 | Albuquerque | New Mexico | In reclutamento |
| Site 216 | Allentown | Pennsylvania | Interrotto |
| Site 316 | Austin | Texas | In reclutamento |
| Site 218 | Bellflower | California | In reclutamento |
| Site 317 | Blackfoot | Idaho | Ritirato |
| Site 236 | Boise | Idaho | In reclutamento |
| Site 119 | Boise | Idaho | Attivo, non in reclutamento |
| Site 318 | Carlsbad | California | Attivo, non in reclutamento |
| Site 310 | Chicago | Illinois | Attivo, non in reclutamento |
| Site 202 | Cincinnati | Ohio | In reclutamento |
| Site 159 | Clermont | Florida | Interrotto |
| Site 207 | Clinton | Utah | Attivo, non in reclutamento |
| Site 203 | Colorado Springs | Colorado | Attivo, non in reclutamento |
| Site 239 | Conroe | Texas | In reclutamento |
| Site 229 | Creve Couer | Missouri | Ritirato |
| Site 102 | Dallas | Texas | Attivo, non in reclutamento |
| Site 343 | Denver | Colorado | In reclutamento |
| Site 349 | Evergreen | Colorado | Attivo, non in reclutamento |
| Site 345 | Evergreen | Colorado | Attivo, non in reclutamento |
| Site 277 | Fairfax | Virginia | In reclutamento |
| Site 238 | Fayetteville | Georgia | In reclutamento |
| Site 148 | Fort Worth | Texas | Ritirato |
| Site 347 | Fort Worth | Texas | Interrotto |
| Site 217 | Glendale | California | Attivo, non in reclutamento |
| Site 279 | Hattiesburg | Mississippi | Ritirato |
| Site 199 | Hickory | North Carolina | Attivo, non in reclutamento |
| Site 320 | Houston | Texas | In reclutamento |
| Site 275 | Houston | Texas | In reclutamento |
| Site 215 | Jackson | Mississippi | Attivo, non in reclutamento |
| Site 335 | Lafayette | California | In reclutamento |
| Site 335 | Lafayette | California | In reclutamento |
| Site 344 | Las Vegas | Nevada | In reclutamento |
| Site 209 | Los Angeles | California | Attivo, non in reclutamento |
| Site 240 | Mankato | Minnesota | In reclutamento |
| Site 201 | Marrero | Louisiana | Interrotto |
| Site 219 | Mather | California | In reclutamento |
| Site 350 | Media | Pennsylvania | Ritirato |
| Site 225 | Miami Gardens | Florida | Attivo, non in reclutamento |
| Site 190 | Miami Lakes | Florida | Attivo, non in reclutamento |
| Site 265 | Minneapolis | Minnesota | In reclutamento |
| Site 194 | Mission Viejo | California | Interrotto |
| Site 206 | Missouri City | Texas | Ritirato |
| Site 198 | Monroe | Louisiana | Interrotto |
| Site 267 | Moorpark | California | In reclutamento |
| Site 352 | Moosic | Pennsylvania | Attivo, non in reclutamento |
| Site 283 | New York | New York | In reclutamento |
| Site 319 | New York | New York | Attivo, non in reclutamento |
| Site 214 | Norwalk | Connecticut | Ritirato |
| Site 161 | Okeechobee | Florida | Attivo, non in reclutamento |
| Site 195 | Oklahoma City | Oklahoma | Interrotto |
Nella scheda del registro sono indicati altri 25 centri.
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 26 ottobre 2026
Obiettivo di arruolamento modificato
Enrollment target revised up from 321 to 325
321325
- 26 ottobre 2026
Centro aggiunto
30 sites added (75 total)
4575